For COVID-19 Detection and Epidemiology, xMAP® Technology Offers Unique Advantages

Multiplex serology tests have yielded impressive results, showing promise for use in the COVID-19 pandemic. xMAP-based serology tests have been widely implemented for the detection of pathogenic bacteria, viruses, and parasites. In the COVID-19 era, xMAP Technology has helped build several new multiplex serology tests designed to detect antibodies to different SARS-CoV-2 antigens. To demonstrate [Read More…]

Webinar: Mount Sinai Scientists Design Multiplex COVID-19 Antibody Test

Implementing xMAP® Technology allows for faster, more accurate results When the global outbreak hit the US, the Icahn School of Medicine at Mount Sinai in New York City published some of the earliest COVID-19 studies in the US. It’s no surprise then that scientists at Mount Sinai were among the first to develop an antibody test. [Read More…]

The Faces of Luminex: Miranda Chavez, Manufacturing and QA Operations

As Luminex® has grown over the years, so have our manufacturing capabilities and the various operations supporting them. We are grateful for employees like Miranda Chavez, Project Manager for Global Manufacturing and Quality Assurance Operations, who keeps things running smoothly. The Austin native earned her bachelor’s in biochemistry at St. Edward’s University and has been [Read More…]

How to Reduce Coupling Variability with Luminex Bead Assays

Top 10 tips for a successful coupling process If you’re designing a new multiplex bead-based assay or adding new targets to an existing xMAP® Technology-based assay, the coupling process required to add a protein or an antibody can seem daunting. We’re here to help! While the Luminex custom assay development service can help you with [Read More…]

xMAP® Technology Users Battle COVID-19 with New Serology Assays

Designed and built by researchers around the world, xMAP® assays shine light on the antibody response to SARS-CoV-2. Our xMAP® Technology empowers researchers to build their own assays quickly, creatively, and effectively. Designed and built by researchers around the world, xMAP® assays shine light on the antibody response to SARS-CoV-2. If you haven’t seen the [Read More…]

The Faces of Luminex: Gabby Mora, Technical Training

Here at Luminex, we know that even the best assays or instruments aren’t worth much if they’re impossible to use. Our developers strive to make sure our products are designed for ease of use, and we also work hard to provide plenty of training opportunities to ensure that all of our customers feel fully supported. [Read More…]

Luminex Supports New Award for Scientific Contributions to Cytokine and Interferon Biology

At Luminex, we believe in the value of recognizing excellence, which is why we are excited to support a new award through the International Cytokine & Interferon Society. The ICIS-LUMINEX John R. Kettman Award for Excellence in Interferon & Cytokine Research will be given to a mid-career investigator who has made exceptional contributions to the [Read More…]

The Faces of Luminex: Ede Brooks McCullough, Marketing

At Luminex, we pride ourselves on developing high-quality molecular diagnostic tests, but this year our commitment to these tests—especially respiratory tests—has been more important than ever. We’re lucky to have Ede Brooks McCullough, Americas Marketing Manager, Respiratory, overseeing our rapidly growing assay portfolio in the Americas for everything from influenza to the SARS-CoV-2 virus. A [Read More…]

Coming Soon: A New Multiplex Serology Test for SARS-CoV-2

Luminex Partner Tetracore designed a serology assay for SARS-CoV-2 using xMAP® Technology. A new multiplex serology test to determine whether someone has been exposed to the SARS-CoV-2 virus is coming soon, thanks to assay developer Tetracore. The company—one of Luminex’s research partners—developed this test based on our xMAP Technology. We spoke with Tetracore Senior Scientist [Read More…]